-+ 0.00%
-+ 0.00%
-+ 0.00%
GSK’s Velzatinib Receives Japan Orphan Drug Designation For GIST, Supported By StrateGIST 1 Data; Adds To US FDA Fast Track, US, EU ODDs, Phase III Trials Under Way
Share
Listen to the news
  • Designation supported by StrateGIST 1 data showing promising anti-tumour activity and tolerability profile
  • Adds to US FDA Fast Track Designation and ODDs in the US and EU
  • Phase III studies accelerated in first- and second-line GIST 
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending